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Purpose: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal
injections for treating exudative age-related macular degeneration.
Methods: Fifteen patients with unilateral exudative age-related macular degeneration
were enrolled. The best-corrected visual acuity was measured and spectral domain optical
coherence tomography was performed at baseline and monthly. Full-field electroretinog-
raphy and multifocal electroretinography were obtained at baseline and 4, 13, and 26
weeks after the first injection. All patients received three monthly intravitreal injections of
ziv-aflibercept (1.25 mg) followed by as-needed treatment.
Results: Between baseline and 26 weeks, the mean logMAR best-corrected visual acuity
improved (P = 0.00408) from 0.93 ± 0.4 (20/200) to 0.82 ± 0.5 (20/160) logarithm of the minimum
angle of resolution, respectively; the central retinal thickness decreased significantly (P = 0.0007)
from 490.3 ± 155.1 microns to 327.9 ± 101.5 microns; the mean total macular volume decreased
significantly (P, 0.0001) from 9.51 ± 1.36 mm3 to 8.08 ± 1.34 mm3, and the a-wave implicit time
increased, with no differences in the other full-field electroretinography parameters. The average
multifocal electroretinography macular responses within the first central 15° showed significantly
(P, 0.05) increased P1 amplitudes at 26 weeks. No systemic or ocular complications developed.
Conclusion: Intravitreal ziv-aflibercept significantly improved the best-corrected visual
acuity, multifocal electroretinography amplitudes, central retinal thickness, and total
macular volume from baseline to 26 weeks. No retinal toxicity on full-field electroretinog-
raphy or adverse events occurred during the follow-up period.
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Age-related macular degeneration (AMD) is theleading cause of legal blindness and central visual
loss in industrialized nations, with patients above the age
of 65 years primarily affected.1 Aflibercept, a recombinant
fusion protein engineered to bind all isoforms of
VEGF-A, VEGF-B, and placental growth factor, received
U.S. Food and Drug Administration approval in Novem-
ber 2011 for treating exudative AMD.2,3 Ziv-aflibercept
(Zaltrap; codeveloped by Sanofi-Aventis and Regeneron
Pharmaceuticals, Inc), a fully humanized soluble re-
combinant fusion protein created by fusing extracellular
Ig domain 2 of VEGFR-1 and extracellular Ig domain 3
of VEGFR-2 to the Fc (constant) region of human IgG1,
was approved by the Food and Drug Administration in
2012 for treating metastatic colorectal carcinoma under
intravenous administration.4,5 However, ziv-aflibercept
has higher osmolarity compared with aflibercept, which
was hypothesized to cause retinal toxicity.6,7
In an experimental rabbit model used to evaluate the
retinal safety of intravitreal ziv-aflibercept, our research
group showed that all eyes had normal funduscopic,
tomographic, and electrophysiologic findings 24 hours
and 7 days after one intravitreal injection of 0.05 mL
(25 mg/mL).8 Intravitreal ziv-aflibercept also has been
studied to treat various exudative macular disorders,
including exudative AMD, diabetic macular edema
(DME), and vein occlusion–related macular edema.9–17
Although the efficacy and lack of toxicity have been
reported, a longer follow-up study of the treatment of
exudative AMD has not been conducted.
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Until now, intravitreal injections of various anti-
VEGF drugs, including aflibercept, have been the best
strategy for treating exudative AMD, but the price of
the currently approved drugs must be considered. Ziv-
aflibercept recently drew attention as an alternative
treatment strategy for exudative AMD because it is
cheaper than aflibercept. When a 4-mL bottle of ziv-
aflibercept is fractioned in 30 doses (0.05 mL), it costs
almost 30 times less than aflibercept. The aim of this
study was to evaluate the safety and efficacy of
intravitreal injections of ziv-aflibercept for treating
exudative AMD during a 6-month follow-up period.
Methods
Study Design
This study was a prospective, interventional, non-
randomized clinical trial that adhered to the tenets of the
Declaration of Helsinki. The Ethics Committee of the
Federal University of São Paulo (Institutional Review
Board number 707.034) and the National Research
Ethics Commission (CONEP) approved the study pro-
tocol. This study was registered at clinicaltrials.gov
(NCT02556723). All patients provided informed con-
sent for the research before screening and after expla-
nation of the nature and possible consequences of
participation. The primary outcome was assessed at
26 weeks (approximately 6 months), and a longer
follow-up is planned through 52 weeks (approximately
12 months). This study reports only the 26-week data.
The major eligibility criteria included patients above
50 years and the presence in the study eye (1 eye per
patient) of active subfoveal or juxtafoveal choroidal
neovascularization secondary to AMD. The main out-
come measure was the safety of intravitreal ziv-
aflibercept. The best-corrected visual acuity (BCVA)
was not a major eligibility criterion, and patients with
a low visual acuity were included. The first four patients
included in this study were consecutive patients from the
Retina Sector of the Department of Ophthalmology of
the Federal University of São Paulo who have already
been treated with bevacizumab at least 6 months before
the beginning of the study. The other subjects were
consecutive patients presenting exudative AMD coming
from the Ophthalmology Emergency Room of the
Federal University of São Paulo.
Patients were excluded if any of the following
were present: other causes of choroidal neovascula-
rization in either eye; bilateral active choroidal
neovascularization; previous laser therapy or ocular
surgery in the study eye such as macular trans-
location surgery, pars plana vitrectomy, glaucoma
filtering surgery, verteporfin photodynamic therapy
(Visudyne; QLT Inc, Vancouver, BC, Canada), and
subfoveal focal laser photocoagulation; history of
active uveitis; uncontrolled diabetes mellitus and
hypertension; history of cerebrovascular accident or
myocardial infarction within 6 months of study entry;
renal failure requiring dialysis or renal transplant;
pregnancy or lactation; or history of allergy to
fluorescein or povidone-iodine.
Assessments
All patients were evaluated every 4 weeks. A retina
specialist (V.F.K.) performed a comprehensive oph-
thalmic examination of both eyes that included
measurement of the BCVA measured using the Early
Treatment Diabetic Retinopathy Study chart, intraoc-
ular pressure measurements by Goldmann applanation
tonometry, dilated fundus examination, slit-lamp ex-
aminations, and imaging with fundus photography,
spectral domain optical coherence tomography (OCT),
and fluorescein angiography (FA). Indocyanine green
angiography was performed in doubtful cases to rule
out other causes of choroidal neovascularization.
Optical coherence tomography was performed at every
visit; FA and fundus photography were performed at
baseline and 26 weeks after treatment initiation.
Optical coherence tomography was performed with
the Spectralis spectral domain OCT instrument
(Heidelberg Engineering, Heidelberg, Germany). The
central retinal thickness (CRT) was defined as the mean
thickness of the neurosensory retina in a central 1-mm-
diameter area, and total macular volume (TMV) was
defined as the total volume of the scanned neurosensory
retina covering a 20-degree · 20-degree (5.7 · 5.7 mm)
macular volume cube. The eye-tracking feature of the
Spectralis spectral domain OCT was used to evaluate
the same area during the follow-up visits. Because the
instrument error was inexact identification of the retinal
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layer segmentation, the incorrectly placed points were
manually repositioned.
The Heidelberg Retina Angiograph 2 (Heidelberg
Engineering) was used to perform FA and, in some
cases, indocyanine green angiography. Fundus photog-
raphy was performed using the Topcon TRC-50IX or
Topcon TRC-50DX (Topcon, Tokyo, Japan). Multifocal
(mfERG) and full-field electroretinography (ffERG) were
performed at baseline and 4, 13, and 26 weeks after the
treatment initiation (Veris Pro 6.3.2; EDI, Redwood City,
CA). Adverse events were recorded at each visit.
The cataract status was recorded at baseline and 12
weeks and 26 weeks as a safety measure and as a possible
confounding factor for visual acuity assessment. The
intraocular pressure was measured at baseline and at 4, 8,
13, 17, 21, and 26 weeks.
The ffERGs were performed after minimal pupillary
diameter of 6 mm obtained after instillation of 1 drop
each of tropicamide 1% and phenylephrine 10%, and
the subjects were dark-adapted for 30 minutes. The
corneal surface was anesthetized with drops of
tetracaine (1.0%) and, under dim red illumination,
a bipolar contact lens electrode (Burian-Allen;
Hansen Ophthalmic Laboratories, Iowa City, IA)
was placed on the corneal surface. A drop of 2%
methylcellulose was placed on the inside surface of
the contact lens for protection and to ensure good
electrical contact. A gold cup to ground the electrode
was applied to the earlobe. The visual response
imaging system software was used with the FMSIII
stimulator running at 75 Hz (EDI). Dark-adapted 0.01
ERGs (rod response), dark-adapted 3.0 ERGs (com-
bined responses), dark-adapted 3.0 oscillatory poten-
tials, light-adapted 3.0 ERGs (cone response), and
light-adapted 3.0 flicker responses (cone-pathway
response) were recorded. The ERGs were recorded
based on the International Society for Clinical
Electrophysiology of Vision guidelines. The peak-
to-peak amplitudes (microvolts) and implicit times
(milliseconds) from each step of the standard protocol
were determined.17
The mfERGs were recorded monocularly after full
pupillary dilation and at least 10 minutes of light
adaption in ambient room illumination (illuminance of
testing room, 255 lux). A fundus camera was used to
monitor fixation, and the optics corrected the refractive
error for the test distance. Recordings were acquired
with the same type of bipolar contact lens electrode
used to record the ffERGs. The amplifier gain was
50,000, and the bandpass was 10 Hz to 300 Hz. The
visual stimuli for the mfERGs consisted of 103 black
and white hexagons (0.45 and 280 cd/m2, respectively),
alternating in a semirandom sequence, modulated ac-
cording to a binary m-sequence. The visual stimuli were
scaled in size with eccentricity (Veris Hexagon 103)
and displayed on a high-resolution black-and-white
camera-refractor monitor, driven at a frame rate of
75 Hz. The surround luminance was 100 cd/m2. Each
m-sequence lasted approximately 7 minutes and was
divided into 16 segments lasting 28 seconds each.
The mfERGs were extracted from the ERG recording
and digitized by an analog-to-digital interface at a sam-
pling rate of 1,200 Hz. The Veris algorithm was used to
extract the local retinal responses.
The mfERG recordings were analyzed by measuring
the N1 and P1 (N1 indicated the first negative wave and
P1, the first positive wave) amplitudes (in nanovolts/de-
grees2), and the implicit times (in milliseconds) for local
ERG responses, in six equally spaced, concentric rings
around a central disk at 0, 5, 10, 15, 20, and 25°. The
Veris software by default calculates an array of first-
order focal ERG kernel traces, one from each stimulated
area, by cross-correlation. The trace array contains the
information about cone function within the tested
areas.18,19 Response densities (nanovolts/degree2) at each
eccentricity from fixation were analyzed and compared
with the normative data from our laboratory.
Intervention
All patients received three monthly 0.05-mL intra-
vitreal injections of ziv-aflibercept (25 mg/mL) (total
dose, 1.25 mg). Commercially acquired ziv-aflibercept
was repackaged in glass vials in an aseptic filling
facility with no dilution maintaining the same original
chemical properties, such as the osmolarity of 1,000
mOsm. All injections were administered according to
a standardized method.20 No topical or systemic anti-
biotics were prescribed before or after the injections.
Retreatment Criteria
After a 3-month loading phase, patients were reas-
signed to an as-needed treatment with the same dose of
ziv-aflibercept administered during the loading phase.
The as-needed treatment regimen was administered if
the patient had any of the following criteria in the study
eye: a greater than 100-mm increase in CRT compared
with the lowest previous treatment; loss of 5 or more
letters of BCVA; new, recurrent, or persistent subretinal
or intraretinal fluid based on OCT; or new macular
hemorrhage or a hemorrhagic area exceeding more than
50% of the disk area. Decisions about retreatment were
also made based on the investigator’s evaluation of the
BCVA, ophthalmic examination results, and OCT and
FA images, according to a Phase 2 study that evaluated
a novel intravitreal anti-VEGF drug.21
All patients were instructed to return 1 month after
the injection for an ophthalmologic evaluation or to
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return promptly if signs and symptoms of endoph-
thalmitis, retinal detachment, or vitreous hemorrhage
developed.
Outcomes
The primary safety outcome was the evaluation of
ffERG changes over time when the baseline findings
were compared with those at 4, 13, and 26 weeks. The
secondary outcomes at 26 weeks were the changes in
the N1-P1 amplitudes and implicit times on the
mfERGs, mean changes in the BCVA values from
baseline over time, incidence rates of adverse events,
mean changes in the CRT and TMV, and the mean
number of injections. The electrophysiologic assessors
(J.M.P. and S.E.S.W.) were masked to the patient
treatments. An unmasked physician (J.R.d.O.D.) eval-
uated all OCT and FA images.
Statistical Methods
For categorical variables, the absolute and relative
frequencies are reported, and for numerical variables,
the means and SDs are reported.
The mean BCVA, CRT, TMV, mfERG parameters
(N1-P1 amplitudes, N1 and P1 implicit times), and
ffERG parameters (amplitudes and implicit times of
the rod responses, b- and a-waves of the dark-
adapted combined responses, oscillatory potential re-
sponses, cone responses, and 30-Hz flicker responses)
were compared between baseline and 26 weeks.
For some ffERG parameters (scotopic b-wave ampli-
tudes, combined maximal a-wave amplitudes, combined
maximal b-wave amplitudes, and cone-response b-wave
amplitudes), we calculated the differences between
baseline and 26 weeks and then compared those differ-
ences between the examined and control eyes. All the
comparisons were performed using the Student’s t-test
for paired samples. P, 0.05 was considered significant.
Statistical analyses were performed using Stata/SE 12.0
statistical software (StataCorp, College Station, TX).
Results
Patient Characteristics
Between July 2014 and July 2015, 16 patients with
exudative AMD in one eye were enrolled. One patient
was excluded because of concomitant branch retinal
vein occlusion in the study eye. Fifteen patients (10
men, 5 women; mean age ± SD, 70.2 ± 8.2 years) met
the study criteria and all completed the 26-week
follow-up. Thirteen (86.7%) eyes were phakic and 2
(13.3%) were pseudophakic.
The mean intraocular pressure was 14.7 ± 2.8
mmHg before treatment and 13.4 ± 2.1 mmHg after
treatment (P = 0.3506). Up to and including Week 26,
8 patients received 3 injections (loading dose), 5 pa-
tients received four injections, and 2 patients received
6 intravitreal injections of ziv-aflibercept in the study
eye. Two patients received the injection on Week 26
(Patients 5 and 10) because of subretinal fluid, and one
patient due to new intraretinal fluid (Patient 13) on this
week. Table 1 shows the baseline characteristics and
the number of injections each patient received.
Table 1. Patient Demographics, Number of Intravitreal Ziv-Aflibercept Injections, and Change in BCVA After Intravitreal
Ziv-Aflibercept






Change in BCVA After Intravitreal Injection of Ziv-Aflibercept
BCVA at 4 Weeks,
Snellen
BCVA at 26 Weeks,
Snellen
1 90 M 3 20/800 20/500 20/400
2 66 M 3 20/500 20/630 20/400
3 70 M 4 20/200 20/125 20/160
4 75 F 3 20/63 20/50 20/63
5 75 M 6 20/160 20/160 20/125
6 75 M 3 20/800 20/400 20/800
7 62 M 3 20/100 20/100 20/50
8 80 F 3 20/125 20/80 20/100
9 69 M 4 20/80 20/50 20/40
10 67 F 6 20/63 20/40 20/63
11 59 F 4 20/200 20/63 20/20
12 74 M 3 20/320 20/400 20/500
13 74 M 4 20/500 20/630 20/400
14 58 F 3 20/63 20/80 20/63
15 69 M 4 20/80 20/63 20/80
Mean 70.2 (8.2) P = 0.00408
F, female; M, male.
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Efficacy
Before treatment, the mean Snellen BCVA of the
eyes in the study group was 20/200 (logarithm of the
minimum angle of resolution [logMAR], mean ± SD,
0.93 ± 0.4; median, 20/160 [logMAR 0.88]; range, 20/
800 ± 1.6 to 20/63 ± 0.5). During the 26-week follow-
up, the mean BCVA improved to 20/160 (logMAR,
mean ± SD, 0.82 ± 0.47; median, 20/125 [logMAR
0.74]; P = 0.00408; Student’s t-test; range, 20/800 ±
1.54 to 20/20 ± 0.06) (Table 1).
Morphologic improvement was monitored based on
the CRT and TMV measurements. The CRT (mean ±
SD) measured by OCT decreased significantly (P =
0.0007) from the baseline value of 490.3 ± 155.1 mi-
crons to 327.9 ± 101.5 microns 26 weeks after treat-
ment, representing an overall decrease of 33.13%. The
mean TMV decreased significantly (P , 0.0001) from
9.51 ± 1.36 mm3 at baseline to 8.08 ± 1.34 mm3 at 26
weeks (Table 2, Figure 1).
Multifocal Electroretinography
Comparison of the N1-P1 amplitudes and N1 and P1
implicit times of the mfERGs at baseline and 4, 13,
and 26 weeks after the start of treatment showed sig-
nificant differences in the N1-P1 amplitudes (Table 3,
Figure 1) but not in the N1 and P1 latencies.
Safety
Thirteen patients underwent 4 ffERGs each at
baseline and 4, 13, and 26 weeks after the start of
treatment. One patient underwent only two ffERGs
(baseline and 4 weeks) and refused the other two ERG
examinations. A total of 58 ffERGs were performed,
and a significant increase in the a-wave implicit times
was observed 26 weeks after treatment. No significant
changes between baseline and the 26-week results
were observed for the other ffERG parameters (Table
3). No significant (P , 0.05) differences were seen
when the ffERG components of the treated and fellow
eyes were compared during the 26-week follow-up
period (Table 4).
Adverse Events
Intravitreal ziv-aflibercept was well tolerated. The
most common ocular adverse events (0.08%) were
associated with the intravitreal injection procedure,
that is, vitreous floaters (one patient), punctate kera-
titis, and conjunctival abrasion related to povidone-
iodine (two patients). None of the patients presented
anterior chamber or vitreous inflammation.
During the 26-week follow-up, no retinal detach-
ment, anterior or posterior uveitis, vitreous hemorrhage,
or endophthalmitis developed. No systemic (nonocular)
adverse events were related to the study drug. There
were no cardiovascular or cerebrovascular events such
as heart failure, stroke, or arterial thrombosis.
Discussion
This study evaluated the safety and efficacy profiles of
intravitreal ziv-aflibercept, a systemic chemotherapeutic
agent approved to treat metastatic colorectal cancer.5,22


















1 538 520 522 8.47 9.33 8.19
2 812 263 281 11.02 8.29 8.23
3 325 247 240 9.12 8.64 8.37
4 334 217 202 9.13 7.66 7.31
5 464 506 344 9.9 10.84 7.68
6 532 283 300 11.19 8.92 8.93
7 548 382 267 8.27 7.09 6.1
8 430 313 239 9.08 8.88 7.92
9 408 327 331 7.67 6.47 6.66
10 655 417 492 12.78 9.79 10.34
11 545 307 324 9.04 8.24 8.52
12 537 372 349 10.38 8.72 9.58
13 375 244 375 9.82 8.12 10.09
14 192 159 174 8.51 7.41 7.55
15 659 558 418 8.31 6.65 5.71
P 0.0007 ,0.0001
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Ziv-aflibercept and aflibercept have the same structure but
aflibercept undergoes a different purification process and
contains different buffer solutions that are less irritating
when injected intravitreally.23 Intravitreal aflibercept also
comes in an iso-osmotic aqueous solution, and it
is approved to treat exudative AMD, DME, and retinal
vein occlusion–related macular edema. However, ziv-
aflibercept is hyperosmolar (1,000 mOsm/L) compared
with the vitreous, and it is administered intravenously.23,24
No current patients had increased intraocular pressure
or cataract progression 26 weeks after intravitreal
injections of ziv-aflibercept, and no severe ocular
adverse events developed, which agrees with other
reports.9–16 Mansour et al10 studied the safety profile of
1.25 mg of intravitreal ziv-aflibercept in four patients
with exudative AMD and two patients with DME and
reported a significant decrease in the height of the fo-
veolar detachment of the retinal pigment epithelium and
improved vision. In this study, the follow-up period was
longer, the mean CRT decreased, and the BCVA
improved. However, the BCVA decreased in one
patient (Case 12) from 20/320 to 20/500. It could be
explained by the subretinal fibrosis this patient already
presented at baseline, and which persisted at 26 Weeks.
Our patients underwent mfERG recordings, an
electrophysiologic method that evaluates localized
retinal or macular areas and can be used as a parameter
of efficacy after intravitreal injections.25,26 The current
result showed that eyes treated with ziv-aflibercept
had increased mfERG amplitudes derived from the
Fig. 1. Representative examinations of the left eye of a patient submitted to intravitreal ziv-aflibercept (Patient 7). A. Fundus picture of the left eye at
baseline reveals choroidal neovascularization secondary to AMD; (B) Fundus picture of the same eye 26 weeks after intravitreal ziv-aflibercept in-
jections; (C) FA before treatment; (D) FA 26 weeks after treatment with intravitreal ziv-aflibercept; (E–G) OCT image (scan length: 6 mm, horizontal
section) at baseline, 4, and 26 weeks after treatment initiation; (H–J) 3-Dimensional response density plots at baseline, 4, and 26 weeks, showing
increase in response amplitude; (K–M) Multifocal electroretinography trace array at baseline, 4, and 26 weeks.
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central retina (0–15°), whereas no changes were seen
in the bioelectrical responses of the other retinal areas
(20 and 25°) or in the N1 and P1 implicit times. We
believe that the improved mfERG central amplitudes,
associated with decreases in central macular thickness
and TMV showed the electrophysiological and struc-
tural effectiveness of ziv-aflibercept. Moschos et al
reported a linear relationship between the visual acuity
and P1 response amplitudes in eyes with AMD treated
with bevacizumab, suggesting that this anti-VEGF
drug improved the retinal function.27 A correlation
between mfERG retinal response density in the central
15° and retinal thickness also was seen in 4 eyes after
bevacizumab treatment, resulting in improved mfERG
macular function responses with decreased CRT mea-
sured by OCT.28
Table 4. Comparison Between the Treated and Control Eye Mean ffERG Parameters at Baseline and 26 Weeks After
Intravitreal Ziv-Aflibercept
Parameters Baseline 4 Weeks 13 Weeks 26 Weeks Difference P
ffERG
Scotopic b-wave amplitude, mV
Treated 68.5 (28.3) 79.6 (47.1) 67.3 (37.6) 81 (45) 212.5 (38.7) 0.1055
Control 76 (38.4) 82.5 (50.4) 67.9 (33.9) 78.8 (44) 22.9 (37.8)
Combined maximal a-wave amplitude, mV
Treated 124.8 (35.7) 127.1 (54.8) 118.2 (48.3) 109.7 (42.1) 15.2 (35.4) 0.9192
Control 133.2 (44.1) 125.7 (45) 122.5 (46) 117.3 (59.6) 15.9 (33.4)
Combined maximal b-wave amplitude, mV
Treated 247.5 (71) 261.6 (91.5) 245.4 (78.7) 253.6 (91) 26.1 (61.8) 0.4240
Control 269.1 (86.3) 266.5 (98.1) 254.1 (77.6) 262.1 (113.3) 7 (76.7)
Cone response b-wave amplitude, mV
Treated 94.5 (25.3) 93.4 (29.5) 93.6 (41.4) 96.6 (35.8) 22.1 (21.5) 0.3046
Control 99.3 (37) 101.2 (37.2) 97.9 (42.3) 95 (33.5) 4.3 (20.4)
Included functional results before and after 4, 13, and 26 weeks of treatment. Data are mean (SD).
Table 3. Mean ffERG and Mean mfERG Data at Baseline and 26 Weeks After Intravitreal Ziv-Aflibercept




Scotopic b-wave amplitude, mV 68.5 (28.3) 81 (45) 0.2470
Scotopic b-wave implicit time, ms 92.1 (13.1) 92.3 (8.4) 0.9541
Combined standard flash
Combined maximal a-wave amplitude, mV 124.8 (35.7) 109.7 (42.1) 0.1334
Combined maximal a-wave implicit time, ms 19.9 (3.2) 21.3 (2.9) 0.0245*
Combined maximal b-wave amplitude, mV 247.5 (71) 253.6 (91) 0.7165
Combined maximal b-wave implicit time, ms 47.6 (4.7) 49 (2.7) 0.1266
OP amplitude, mV 24.2 (11.3) 21.4 (16.6) 0.3827
OP implicit time, ms 26.2 (1.9) 26.1 (1) 0.7727
Light-adapted
Cone response b-wave amplitude, mV 94.5 (25.3) 96.6 (35.8) 0.7152
Cone response b-wave implicit time, ms 34.7 (1.8) 34.3 (1.5) 0.4264
30-Hz flicker amplitude, mV 80.4 (32.7) 82.5 (42.4) 0.6953
30-Hz flicker implicit time, ms 32 (2.8) 32 (2.7) 0.9549
Multifocal ERG
N1-P1 amplitude 0°, nV/deg2 18.13 (5.84) 25.88 (12.72) 0.034*
N1-P1 amplitude 5°, nV/deg2 12.25 (4.11) 17.21 (6.02) 0.0021*
N1-P1 amplitude 10°, nV/deg2 12.23 (3.37) 15.34 (5.67) 0.0079*
N1-P1 amplitude 15°, nV/deg2 12.14 (3.48) 14.09 (4.93) 0.0315*
N1-P1 amplitude 20°, nV/deg2 12.68 (2.98) 13.91 (4.06) 0.1082
N1-P1 amplitude 25°, nV/deg2 13.86 (4.37) 14.98 (4.7) 0.0927
Includes functional results before and after 26 weeks of treatment. Data are mean (SD).
The ffERG showed increase in a-wave implicit time at Week 26. The mfERG N1-P1 amplitude improved significantly at Week 26 from 0°
to 15°.
*Significance level of pairwise comparison to baseline results (P # 0.05).
OPs, oscillatory potentials.
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Other studies have reported that ffERG can be
a functional tool for evaluating retinal toxicity after
intravitreal injections.14,28,29 In this study, an increase
in the a-wave combined response implicit time was
the only ffERG parameter that changed significantly
during follow-up. We believe that this might have
occurred because of our small sample, because
the main ffERG markers of retinal toxicity (rod
response, oscillatory potentials, and 3.0 flicker) re-
mained unchanged over time. In a study in which
patients with DME underwent monthly intravitreal
ziv-aflibercept injections, no significant differences
were found in the amplitudes or implicit times of
any ffERG components, and the visual acuity
improved with decreases in CRT observed over 24
weeks.14
We believe the low number of injections per patient
could be related to the late AMD stage that most of the
patients already presented at baseline, especially
because of the presence of subretinal fibrosis. It
somewhat reflects the reality of developing countries
in which patients with exudative AMD wait several
months for evaluation and treatment in a tertiary care
system. Patients with a recently diagnosed exudative
AMD would be expected to need more injections. As
some of the patients only received three intravitreal
injections of ziv-aflibercept, a study with monthly
injections in patients with exudative AMD is needed
to confirm the absence of toxicity of ziv-aflibercept.
A recently published article in which patients pre-
senting DME were submitted to monthly intravitreal
ziv-aflibercept injections during 6 months did not
show any ffERG signs of retinal toxicity. According
to this study, escalating doses would not lead to
retinal toxicity.14
The limitations of this study were the small number
of patients, with 11 treatment-naive patients; the
nonrandomized design; and the short follow-up period.
Except for one patient, all patients underwent 4
ffERGs and 4 mfERGs from baseline to 26 weeks,
which may be a good strategy for monitoring the
treatment safety and efficacy, respectively. To the best
of our knowledge, this study is the only one that has
evaluated the treatment efficacy of intravitreal ziv-
aflibercept with mfERGs.
Ziv-aflibercept may be a safe and effective alterna-
tive treatment for exudative AMD. A longer follow-up
is required to confirm if repeated injections or dose
escalations increase the risk of ocular adverse events
or retinal toxicity.
Key words: ziv-aflibercept, age-related macular
degeneration, full-field electroretinography, multifocal
electroretinography.
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